Dolutegravir-rilpivirine: first 2-drug regimen for HIV-positive adults

Does simplification to dolutegravir-based dual regimens impact on the CD4+/CD8+ T-cell ratio?

(2018) Amedeo F. Capetti et al.   AIDS

Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data

(2018) Amedeo Ferdinando Capetti et al.   ANNALS OF PHARMACOTHERAPY

Adipocytes impair efficacy of antiretroviral therapy

(2018) Jacob Couturier et al.   ANTIVIRAL RESEARCH

Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: a multicenter retrospective cohort study from 2007 to 2015

(2018) Eugenia Quiros-Roldan et al.   BMC INFECTIOUS DISEASES

Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study

(2018) Cristina Mussini et al.   BMC Medicine

Dolutegravir in pregnancy—effects on HIV-positive women and their infants

(2018) Riikka Bornhede et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy

(2018) Simone Belmonti et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

(2018) Josep M Llibre et al.   LANCET

Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals

(2018) Andrew M. Hill et al.   Current Opinion in HIV and AIDS

Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study

(2018) Rebecca Zash et al.   Lancet Global Health

The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial

(2018) Thomas A Rasmussen et al.   Lancet HIV

Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study

(2017) P Gantner et al.   HIV MEDICINE

Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence

(2017) C Orkin et al.   HIV MEDICINE

Dolutegravir reshapes the genetic diversity of HIV-1 reservoirs

(2017) Pierre Gantner et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

HIV drug therapy duration; a Swedish real world nationwide cohort study on InfCareHIV 2009-2014

(2017) Amanda Häggblom et al.   PLoS One

Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice

(2016) Mark G.J. de Boer et al.   AIDS

Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia

(2016) Pornpimol Thamrongwonglert et al.   HIV CLINICAL TRIALS

Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients

(2016) C Hoffmann et al.   HIV MEDICINE

HIV and aging

(2016) Edward J. Wing   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen

(2016) Arkaitz Imaz et al.   JOURNAL OF INFECTIOUS DISEASES

Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort

(2016) Amedeo F. Capetti et al.   PLoS One

Do people with HIV infection have a higher risk of fracture compared with those without HIV infection?

(2016) Jennifer Hoy et al.   Current Opinion in HIV and AIDS

Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis

(2016) Amit C Achhra et al.   Lancet HIV

Bone health in HIV and hepatitis B or C infections

(2016) Emmanuel Biver et al.   Therapeutic Advances in Musculoskeletal Disease

Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients

(2016) Jean-Guy Baril et al.   PLoS One

Projected Uptake of New Antiretroviral (ARV) Medicines in Adults in Low- and Middle-Income Countries: A Forecast Analysis 2015-2025

(2016) Aastha Gupta et al.   PLoS One

Psychiatric disorders after starting dolutegravir

(2015) Farid Kheloufi et al.   AIDS

Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials

(2015) François Raffi et al.   AIDS

Comparative Changes of Lipid Levels in Treatment-Naive, HIV-1-Infected Adults Treated with Dolutegravir vs. Efavirenz, Raltegravir, and Ritonavir-Boosted Darunavir-Based Regimens Over 48 Weeks

(2015) Romina Quercia et al.   CLINICAL DRUG INVESTIGATION

The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States

(2015) Michael P. Girouard et al.   CLINICAL INFECTIOUS DISEASES

HIV-1 CNSin vitroinfectivity models based on clinical CSF samples

(2015) Borja Mora-Peris et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients

(2015) Camelia Gubavu et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Antiretrovirals and the kidney in current clinical practice

(2014) Jean C. Yombi et al.   AIDS

Lipid Levels and Changes in Body Fat Distribution in Treatment-Naive, HIV-1–Infected Adults Treated With Rilpivirine or Efavirenz for 96 Weeks in the ECHO and THRIVE Trials

(2014) Pablo Tebas et al.   CLINICAL INFECTIOUS DISEASES

ING116070: A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in Cerebrospinal Fluid in HIV-1-Infected, Antiretroviral Therapy-Naive Subjects

(2014) S. L. Letendre et al.   CLINICAL INFECTIOUS DISEASES

Evaluation of dolutegravir safety for the treatment of HIV-1

(2014) Susana W Keeshin et al.   Expert Opinion On Drug Safety

Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir

(2013) Mackenzie L. Cottrell et al.   CLINICAL PHARMACOKINETICS

The Next Therapeutic Challenge in HIV: Polypharmacy

(2013) E. Jennifer Edelman et al.   DRUGS & AGING

Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment

(2013) Stephen Weller et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Increase in 2–Long Terminal Repeat Circles and Decrease in D-dimer After Raltegravir Intensification in Patients With Treated HIV Infection: A Randomized, Placebo-Controlled Trial

(2013) Hiroyu Hatano et al.   JOURNAL OF INFECTIOUS DISEASES

Is HIV a Model of Accelerated or Accentuated Aging?

(2013) S. Pathai et al.   JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

(2013) Pedro Cahn et al.   LANCET

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

(2013) Sharon L. Walmsley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada

(2013) Hasina Samji et al.   PLoS One

The history of antiretroviral therapy and of its implementation in resource-limited areas of the world

(2012) Stefano Vella et al.   AIDS

Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents

(2012) Roger Bedimo et al.   AIDS

Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials

(2012) Calvin J. Cohen et al.   AIDS

Rilpivirine

(2012) Mark Sanford   DRUGS

Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin

(2012) Kelly E. Dooley et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor

(2012) M. Sharma et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Tenofovir-Associated Kidney Toxicity in HIV-Infected Patients: A Review of the Evidence

(2011) Andrew M. Hall et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Effects of Etravirine Alone and with Ritonavir-Boosted Protease Inhibitors on the Pharmacokinetics of Dolutegravir

(2011) Ivy Song et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study

(2011) Josep M Llibre et al.   ANTIVIRAL THERAPY

Premature Age-Related Comorbidities Among HIV-Infected Persons Compared With the General Population

(2011) G. Guaraldi et al.   CLINICAL INFECTIOUS DISEASES

Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers

(2011) P. Patel et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

(2011) Calvin J Cohen et al.   LANCET

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

(2011) Jean-Michel Molina et al.   LANCET

Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)

(2011) S. Hare et al.   MOLECULAR PHARMACOLOGY

Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients

(2010) Amanda Mocroft et al.   AIDS

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

(2010) Maria J Buzón et al.   NATURE MEDICINE

TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1

(2009) H. Azijn et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Tenofovir-associated renal and bone toxicity

(2009) CLN Woodward et al.   HIV MEDICINE